Palivizumab for preterm infants. Is it worth it? - Wikidata - awgldk - TriplyDB

Palivizumab for preterm infants. Is it worth it?

Palivizumab for preterm infants. Is it worth it?

http://www.wikidata.org/entity/Q35296973

about

Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology.Acute bronchiolitis The future for lung disease in children Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV)Viral bronchiolitis for the clinician.Preventing severe respiratory syncytial virus disease: passive, active immunisation and new antivirals.Novel therapies and vaccines against the human respiratory syncytial virus.Contribution of Fcγ receptors to human respiratory syncytial virus pathogenesis and the impairment of T-cell activation by dendritic cells.Probiotics to prevent necrotizing enterocolitis: Too cheap and easy?Palivizumab in preventing respiratory syncytial virus-related hospitalization in high-risk infants.The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics.

P2860

Q26830864-FB95736B-E187-4C7D-BFF7-46F7A3C32ED3 Q33591243-F06BA0AB-7918-4786-BDE1-9E93994B2EC6 Q36145677-6F79AAD4-0FEA-4427-B38C-1084F0F3B292 Q36169163-DBB796FD-30ED-4CF4-A1EF-454AAEF1C99B Q37290618-1E5D20E9-556C-40FD-BBAF-38AB1EE1F91F Q37760564-7B1310AC-8E48-470A-869A-02F33D682A44 Q38182054-AE10806F-EE50-4E0E-A340-9A0FD99E66FE Q38604787-154D4EFC-98D9-434C-9A1E-5D676CF02C4F Q40959795-0CE6E995-39C1-4898-AB38-E8B942009212 Q42008659-A09DE6F4-D3B4-400F-BF17-6D42B82EB4E2 Q45375474-B30A375C-3614-4DCE-9129-A68CFB79D552 Q55447639-AF22CEFB-7406-4FE0-B0CB-085D11F3FB3B

P2860

Palivizumab for preterm infants. Is it worth it?

http://www.wikidata.org/entity/Q35296973

description

2005 nî lūn-bûn

@nan

2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

name

Palivizumab for preterm infants. Is it worth it?

@ast

Palivizumab for preterm infants. Is it worth it?

@en

type

label

Palivizumab for preterm infants. Is it worth it?

@ast

Palivizumab for preterm infants. Is it worth it?

@en

prefLabel

Palivizumab for preterm infants. Is it worth it?

@ast

Palivizumab for preterm infants. Is it worth it?

@en

P1433

Q35296973-530F63EA-A11B-444F-8F09-6CDBCA482F4C

P1476

Q35296973-F94FBE0E-C1D3-4185-A9F2-6A0D1EE53CAF

P2093

Q35296973-17056844-1BE4-4B9A-BFB8-1D7E5460C19C

Q35296973-E0D62A3E-BA23-43D6-A905-68AC46CD9BB8

P2860

Q35296973-0D923E15-6900-4F12-94A8-A7156F92F78B

Q35296973-14B1F97F-1943-4008-BCF3-387C4B4EAEB5

Q35296973-3DCBCACC-2A58-4F1C-B0E6-4D8205348A1A

Q35296973-424115B1-8977-48C4-B05F-D4FEFE4C7661

Q35296973-464DDFFD-B8E8-4855-A810-DA734D3980B9

Q35296973-4F1A9870-7E8F-4FE2-A896-C4B9E07DD5B2

Q35296973-526D411C-4F26-4717-9CDD-6EB39B003202

Q35296973-59D267AD-2865-4DB1-8F34-10F6D57420B0

Q35296973-5E631602-BF62-400B-A8AA-375FDC13AD27

Q35296973-699B4C2D-C6EC-4585-930D-D33A4A43A84E

P304

Q35296973-D1F33BE8-90E7-42E6-9B6E-AA1B7B822CF9

P31

Q35296973-D20C6383-A66F-4D75-B981-F04A86F766DC

Q35296973-f6588070-99a9-4601-9502-a5717958d467

P356

Q35296973-F7AFCE6D-C037-4907-ABFD-004B474CF485

P433

Q35296973-69C1737A-C397-4FE3-9592-5B63B539CFC7

P478

Q35296973-F5F34C07-B697-4DD7-B273-186EF4510C2C

P50

Q35296973-58494BF7-1711-408A-8EA5-8438408003B9

P577

Q35296973-CA30B01A-2D84-4764-B90C-0DE198067F8B

P5875

Q35296973-AB590C0B-BC49-4BB0-B875-44E9BF2F05B7

P698

Q35296973-4B5DFE0A-407C-44AA-95A5-433C359EB0E9

P921

Q35296973-16F88C03-344F-4E90-8869-9A152C402B6E

P932

Q35296973-0D60E16F-D9CA-4E4D-AF5D-A8AB087B8CBF

P356

ADC.2004.058081

P1433

Archives of Disease in Childhood. Fetal and Neonatal Edition

P1476

Palivizumab for preterm infants. Is it worth it?

@en

P2093

Harkensee C

http://www.w3.org/2001/XMLSchema#string

Mckean MC

http://www.w3.org/2001/XMLSchema#string

P2860

Prevention of respiratory syncytial virus infection in infants

Respiratory syncytial virus infection.

Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group.

Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection

Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review.

Hospitalisation for RSV infection in ex-preterm infants-implications for use of RSV immune globulin.

The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area

Respiratory syncytial virus bronchiolitis in ex-preterm infants in the Scottish highlands: review of hospital admissions and an analysis of hospital cost.

Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party.

Respiratory syncytial virus.

P304

F286-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ADC.2004.058081

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

90

http://www.w3.org/2001/XMLSchema#string

P50

Nicholas David Embleton

P577

2005-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7708413

http://www.w3.org/2001/XMLSchema#string

P698

16036888

http://www.w3.org/2001/XMLSchema#string

P921

P932

1721903

http://www.w3.org/2001/XMLSchema#string